TD Cowen analyst Daniel Brennan maintained a Hold rating on Qiagen yesterday and set a price target of $48.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Daniel Brennan has given his Hold rating due to a combination of factors impacting Qiagen’s stock. The company’s third-quarter performance showed solid trends with a 6% core growth and a slight earnings per share upside, which were positive indicators. However, the cautious commentary from management and the transition to a new CEO have introduced uncertainties that have weakened the stock’s position.
Despite a small revenue beat and a 7% EPS growth, the long-term growth drivers, excluding QuantiFERON, appeared to be softening, and the outlook for 2026 organic growth remains mixed. The company’s valuation is discounted compared to historical and peer levels, and while Qiagen’s defensive and diversified portfolio is a strength, the path to achieving growth targets could be challenging. These factors, along with a slight reduction in the price target from $50 to $48, contribute to the Hold rating.
In another report released on November 8, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $47.00 price target.